Outcomes Studies Are Key To Validating Metabolic Syndrome As A Disease
Executive Summary
European regulators have indicated that providing data from outcomes trials would be the best way to validate metabolic syndrome as a treatable condition, according to RenaSci Consultancy Director David Heal
You may also be interested in...
Novartis’ Outcome Program May Prove Galvus A GLORIOUS First-Line Therapy
Novartis hopes to establish Galvus as a treatment for use in early stage type 2 diabetes through a program of outcomes trials for the dipeptidyl peptidase IV inhibitor
Novartis’ Outcome Program May Prove Galvus A GLORIOUS First-Line Therapy
Novartis hopes to establish Galvus as a treatment for use in early stage type 2 diabetes through a program of outcomes trials for the dipeptidyl peptidase IV inhibitor
Metabolic Syndrome Reimbursement Forecast: Outlook Remains Cloudy
In the near term, the best prospect for establishing a favorable reimbursement climate for metabolic syndrome may be to focus on treating comorbidities